These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 18161131)

  • 1. [Clinical implications of bisphosphonate for bone metastases of prostate cancer].
    Kitagawa Y; Konaka H; Mizokami A; Namiki M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():356-9. PubMed ID: 18161131
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical study of bisphosphonates for bone metastasis in breast cancer].
    Yamada K; Kohno N
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():352-5. PubMed ID: 18161130
    [No Abstract]   [Full Text] [Related]  

  • 3. [Bisphosphonate treatment against breast cancer with bone metastases].
    Kohno N
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():575-81. PubMed ID: 17682213
    [No Abstract]   [Full Text] [Related]  

  • 4. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
    Saad F; McKiernan J; Eastham J
    Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural history and treatment of bone complications in prostate cancer.
    Saad F; Clarke N; Colombel M
    Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
    Saad F; Colombel M
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1991-2002. PubMed ID: 21110764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
    Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
    Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New research findings on zoledronic acid: survival, pain, and anti-tumour effects.
    Saad F
    Cancer Treat Rev; 2008 Apr; 34(2):183-92. PubMed ID: 18061356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress in treatment of metastatic tumors in the bone by bisphosphonate].
    Dong M; Chen XP; Feng FY
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):801-3. PubMed ID: 18396633
    [No Abstract]   [Full Text] [Related]  

  • 13. Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.
    Saad F; Eastham J
    Urology; 2010 Nov; 76(5):1175-81. PubMed ID: 21056263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of prophylactic effect of incadronate on skeletal lesions associated with implants of prostate cancer.
    Hikosaka A; Futakuchi M; Ogiso T; Suzuki S; Kohri K; Shirai T
    Eur Urol; 2006 Jan; 49(1):176-82. PubMed ID: 16310925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments for treatment and prevention of bone metastases.
    Body JJ
    Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates for treatment and prevention of bone metastases.
    Michaelson MD; Smith MR
    J Clin Oncol; 2005 Nov; 23(32):8219-24. PubMed ID: 16278476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New bone density conservation agents for osteoporosis under research and development: Minodronic acid].
    Takata S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():417-20. PubMed ID: 18161142
    [No Abstract]   [Full Text] [Related]  

  • 18. [Biphosphonates in the treatment of bone metastasis of prostatic cancer].
    Paule B; Cicco A
    Prog Urol; 2001 Dec; 11(6):1205-12. PubMed ID: 11859653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bisphosphonate against patients with hormone refractory prostate cancer].
    Shinohara N
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():576-80. PubMed ID: 22208047
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.